To the best of our knowledge, there are no prospective studies evaluating the efficacy of ICIs plus chemotherapy in driver–oncogene-positive NSCLC other than EGFR mutation and ALK fusion. The gene discussed is ALK; the disease is non-small cell lung carcinoma.